InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Share Price

Current share price for AGN : $0.097 0.013 (11.82%)+

Argenica Therapeutics Limited (AGN), an ASX-listed company, is a Company engaged in research and development of a neuroprotective therapeutic drug. Its neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

AGN General Information +

ASX Code AGN
Website http://www.argenica.com.au
Industry/Sector Pharmaceuticals
Market Cap ($M) 12
AGN Share Price $0.097
Day High $0.105
Day Low $0.097
Last Close $0.110
AGN Share Price Movement $0.01 ( 11.82% )
Prices as at 16:40, 24 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Argenica Therapeutics Limited (AGN) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Argenica Therapeutics Limited (AGN) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Argenica Therapeutics Limited (AGN) price-sensitive announcements

AGN - ARG007 (Xaranetide) Completes All Three FDA Requested Assays
Argenica Therapeutics Limited has announced the successful completion of the final FDA req
Argenica Therapeutics Limited (AGN)
11 Jun 2026 | 8:33 AM
AGN - WHO Confirms Xaranetide as INN for ARG-007
Argenica Therapeutics Limited, an Australian biotechnology company, announced that the Wor
Argenica Therapeutics Limited (AGN)
10 Jun 2026 | 8:19 AM
AGN - IND Application Advanced With Successful Completion of Assay
Argenica Therapeutics Limited announced the successful completion of a GLP-compliant in vi
Argenica Therapeutics Limited (AGN)
21 May 2026 | 9:01 AM
AGN - Clinical Advisory Committee Established to Advance Phase 2b
Argenica Therapeutics Limited announced the formation of a Clinical Advisory Committee to
Argenica Therapeutics Limited (AGN)
14 May 2026 | 9:15 AM

Argenica Therapeutics Limited (AGN) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
Health Care $12 Investor Webinar 11 Jun 2026 8:33AM $0.110 $0.097 fallen by 11.82%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
Health Care $12 Investor Presentation 11 Jun 2026 8:33AM $0.110 $0.097 fallen by 11.82%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
Health Care $12 ARG007 (Xaranetide) Completes All Three FDA Requested Assays 11 Jun 2026 8:33AM $0.110 $0.097 fallen by 11.82%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
Health Care $12 WHO Confirms Xaranetide as INN for ARG-007 10 Jun 2026 8:19AM $0.115 $0.097 fallen by 15.65%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
Health Care $12 Notification of cessation of securities - AGN 9 Jun 2026 2:13PM $0.115 $0.097 fallen by 15.65%
Argenica Therapeutics Limited (AGN)
ORDINARY FULLY PAID
Health Care $12 Release of Securities from Voluntary Escrow 26 May 2026 9:52AM $0.115 $0.097 fallen by 15.65%

AGN Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$7.17 -$5.60 6.40% 0.00 0.00 0.00% 0.0%
2024A -$5.48 -$5.30 -4.00% 0.00 0.00 0.00% 0.0%
2023A -$4.82 -$5.50 -0.50% 0.00 0.00 0.00% 0.0%

AGN Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Argenica Therapeutics Limited (AGN) $13M 0.0644 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Clarity Pharmaceuticals Ltd (CU6) $757M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $1,575M -0.7857 0.0743 1.2000 53.3734 49.6800 22.5818 0.00% 0.00% 0.00%

AGN Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.95 0.00
Market 0.30 13.20 1.17 0.66
Sector 0.42 26.50 2.44 2.33

AGN Directors

Name Position Start Date
Dr Liz Dallimore Chief Executive Officer, Managing Director 4 Apr 2022
Dr Jeannie(Jeannette) Joughin Non-Executive Director 2 Dec 2024
Dr Mark Etherton Non-Executive Director 17 Sep 2024

Argenica Therapeutics Limited (AGN) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 Aug 2024 ANGUS, Dianne Issued Options 500,000 $0.275 $137,727.000
8 Aug 2024 BUDGE, Terrence (Terry) Cancelled Options 181,818 $1.000 $181,818.000
8 Aug 2024 DALLIMORE, Liz Cancelled Options 909,091 $0.825 $750,000.000

See all changes in directors' interest & trades for Argenica Therapeutics Limited (AGN) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

AGN Management

Name Position
Emma Waldon Chief Financial Officer,Company Secretary

AGN Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Argenica Therapeutics Limited (AGN). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
7,835,976 (6.10%) Neil Delroy

AGN Calendar of Events

Date Event
10 February 2027 Report (Interim)
27 August 2026 Report (Annual)
27 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.